-
Cost-Utility Analysis and Value-Based Pricing of Digital Therapeutics for Pulmonary Rehabilitation in Patients With Chronic Respiratory Disease: A Multicenter Randomized Controlled Trial
Mar 10, 2025, 14:00 PM -
Tailoring Generalized Cost-Effectiveness Analysis (GCEA) to the U.S. Setting: the Importance of Using the Right Prices
Mar 10, 2025, 14:00 PM -
Epidemiological and Economic Analysis of Hospitalizations for Cellulitis and Erysipelas From the Perspective of a Brazilian Health Insurance Company
Mar 10, 2025, 14:00 PM -
Surgical Stripping and Ligation Compared to Cyanoacrylate Vein Closure in the Mexican Public Healthcare Setting: Direct Costs and Incapacity Pay
Mar 10, 2025, 14:00 PM -
The Economic Burden of Illness for Patients with Idiopathic Pulmonary Fibrosis Utilizing Treatment Cohorts: A US Retrospective Claims Study
Mar 10, 2025, 14:00 PM -
Willingness to Pay for a Quality Adjusted Life Year Across Different Time Horizons: Direct Elicitation in Quebec
Mar 10, 2025, 14:00 PM -
Content Validation of the Patient Attainment Scale-Essential Tremor (PAS-ET): A Novel Patient-Reported Outcome Measure Assessing Patient-Level Perceptions of the Importance, Current Function and Definitions of Meaningful Improvement in Tremor-Related...
Mar 10, 2025, 14:00 PM -
Choosing Wisely?' Use of Staging Imaging in US Veteran Patients With Prostate Cancer
Mar 10, 2025, 14:00 PM -
Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in US Adults Aged 60 Years with Cardiopulmonary Disease
Mar 10, 2025, 14:00 PM -
Receipt of Guideline Concordant Treatment Among Older Adults Newly Diagnosed With Stage III - IV Melanoma Using SEER-Medicare Linked Data
Mar 10, 2025, 14:00 PM -
Exploring the Impact of Data Availability on Time-Course Model-Based Network Meta-Analysis
Mar 10, 2025, 14:00 PM -
Early Detection of CHAPLE Disease in Pediatric Protein-Losing Enteropathy: A Feasibility Study
Mar 10, 2025, 14:00 PM -
National and State Population-Level Estimated Economic Impact of Ocrelizumab on Cumulative Disabilities Avoided and Work Productivity Under Different Access Scenarios in the United States
Mar 10, 2025, 14:00 PM -
Temporal Trends in Healthcare Costs Associated with First-Line (1L) Nivolumab + Ipilimumab (N+I) and Pembrolizumab + Lenvatinib (P+L) in Advanced or Metastatic Renal Cell Carcinoma (aRCC)
Mar 10, 2025, 14:00 PM -
Characterizing Social Determinants of Health in the Population Receiving Pneumococcal Vaccine in a National Pharmacy Chain in the United States
Mar 10, 2025, 14:00 PM -
Collaborations Between Pharma and Digital Health Startups: Advancing Innovation and Reimbursement in Digital Health Technologies
Mar 10, 2025, 14:00 PM -
Economic Impact of Immunobiological Therapies in Disease Affecting Skin from the Perspective of Population Health Management in LMIC/LATAM/Brazil
Mar 10, 2025, 14:00 PM -
Antidiabetic Medication Uses Among Pregnant Women: Real-World Prescription Pattern in South Korea
Mar 10, 2025, 14:00 PM -
Adapting PRISMA For System Dynamics Models In Healthcare: A Case Study Of Transcatheter Aortic Valve Implantation In Canada
Mar 10, 2025, 14:00 PM -
Developing a Conceptual Framework for a De-novo Cost-Effectiveness Model in Sanfilippo Syndrome (MPSIIIA)
Mar 10, 2025, 14:00 PM
